Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 17,134 matching trials from the live ClinicalTrials.gov search.

Filters: Philadelphia, Pennsylvania Clear all

Conditions: Suicidal Ideation, Suicidal and Self-injurious Behavior, Suicide, Autism Spectrum Disorder
Interventions: Safety Planning Intervention tailored for Autistic Individuals, Safety Planning Intervention Tailored for Autistic Individuals Plus Structured Follow-Up Contacts; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 12 Years to 99 Years
Enrollment: 1,665 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 5
States / cities: Baltimore, Maryland • Chapel Hill, North Carolina • Columbus, Ohio + 2 more

Conditions: Pancreatic Ductal Adenocarcinoma
Interventions: The risk assessment questionnaire, Blood specimens, tumor tissue samples will be requested; Behavioral · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2026
U.S. locations: 10
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 6 more

Conditions: Alcoholism
Interventions: Varenicline, Placebo; Drug
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 7
States / cities: Baltimore, Maryland • Boston, Massachusetts • Bedford, New Hampshire + 4 more

Conditions: Type 2 Diabetes, Cardiovascular Disease
Interventions: TAK-875, TAK-875 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 3,207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 218
States / cities: Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 215 more

Conditions: HIV Infections
Interventions: Interferon beta-1b, Zidovudine; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 25
States / cities: Berkeley, California • Los Angeles, California • Oakland, California + 13 more

Conditions: Platinum-resistant Ovarian Cancer
Interventions: Batiraxcept, Paclitaxel, Placebo; Drug · Other
Lead sponsor: Aravive, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 84
States / cities: Mobile, Alabama • Burbank, California • Los Angeles, California + 74 more

Conditions: HIV Infections, Hepatitis C
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Year to 20 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more

Conditions: Prostate Cancer
Interventions: bicalutamide, radiation therapy, placebo; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: Male only
Enrollment: 840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2022
U.S. locations: 221
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 168 more

Conditions: Obstructive Sleep Apnea
Interventions: Genio™ system; Device
Lead sponsor: Nyxoah S.A.; Industry
Eligibility: 22 Years to 75 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 16
States / cities: Birmingham, Alabama • Boca Raton, Florida • Tampa, Florida + 12 more

Conditions: Atrial Fibrillation
Interventions: Ganglionated Plexi mapping and ablation using Natus Cortical Stimulator and standard ablation catheters; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hepatitis C, Non-Alcoholic Fatty Liver Disease
Interventions: Placebo, Silymarin; Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 5
States / cities: Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 1 more

Conditions: Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy
Interventions: Not listed
Lead sponsor: Wayne State University; Other
Eligibility: Up to 20 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 12
States / cities: Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 9 more

Conditions: Respiratory Syncytial Virus (RSV)
Interventions: Presatovir, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 17
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 14 more

Conditions: In Need of a Pap Smear (Cervical Cancer Screening), In Need of a Blood Pressure Check (Hypertension Screening), In Need of a Cholesterol Test (Lipid Disorder Screening), In Need of a Fasting Plasma Glucose Test (Diabetes)
Interventions: Planning Prompt, Control Condition; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 8,711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
Interventions: Bel-sar, Suprachoroidal Microinjector, Infrared Laser, Sham Infrared Laser, Sham Microinjector; Drug · Device
Lead sponsor: Aura Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 25
States / cities: Los Angeles, California • Palo Alto, California • Sacramento, California + 20 more

Conditions: Locally Advanced Bone Sarcoma, Locally Advanced Dedifferentiated Liposarcoma, Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Soft Tissue Sarcoma, Metastatic Bone Sarcoma, Metastatic Liposarcoma, Metastatic Soft Tissue Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Metastatic Unresectable Sarcoma, Pleomorphic Liposarcoma, Stage III Bone Sarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Bone Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Bone Sarcoma AJCC v7, Stage IVB Bone Sarcoma AJCC v7, Unresectable Bone Sarcoma, Unresectable Dedifferentiated Liposarcoma, Unresectable Liposarcoma, Unresectable Malignant Gastrointestinal Stromal Tumor, Unresectable Soft Tissue Sarcoma
Interventions: Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 651
States / cities: Anchorage, Alaska • Hot Springs, Arkansas • Little Rock, Arkansas + 402 more

Conditions: Broad Solid Tumor
Interventions: BMS-986207, Nivolumab, Ipilimumab; Drug · Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 6
States / cities: Hackensack, New Jersey • New York, New York • Philadelphia, Pennsylvania + 2 more

Conditions: Contraception
Interventions: Woman's Condom; Device
Lead sponsor: Premier Research; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 511 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 10
States / cities: Los Angeles, California • Baltimore, Maryland • New York, New York + 6 more

Conditions: Major Depressive Disorder
Interventions: Escitalopram, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 28
States / cities: Sacramento, California • San Diego, California • Washington D.C., District of Columbia + 23 more

Conditions: Influenza, Human
Interventions: Flu shot text messages; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 74,811 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Danville, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Influenza
Interventions: Peramivir, Placebo Comparator; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 96
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Jonesboro, Arkansas + 93 more

Conditions: Medical Adherence
Interventions: GlowCap, Daily email, text message, or phone call reminders, Paid for adherence; Device · Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 84 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Metastatic Cholangiocarcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Cholangiocarcinoma, Unresectable Hepatocellular Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Carboplatin, Paclitaxel, Pevonedistat; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 419
States / cities: Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 254 more

Conditions: TBI (Traumatic Brain Injury)
Interventions: No intervention. This is an observational study.; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Philadelphia, Pennsylvania

Search by objective public record fields.

A Comparison of Two Brief Suicide Prevention Interventions Tailored for Youth on the Autism Spectrum

A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma

Varenicline for Alcohol Dependence

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen

Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Prevalence of Hepatitis C Virus Infection in HIV-Infected Children

Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy

Dual-sided Hypoglossal neRvE stimulAtion for the treatMent of Obstructive Sleep Apnea (DREAM)

Prospective Evaluation of CT Guided Ablation of Cardiac Ganglionated Plexi

Phase I Trial of Silymarin for Chronic Liver Diseases

Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)

Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection

The Effect of a Coloring Prompt on Health Engagement

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery

A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors

A Multicenter, Open-Label, Non-Comparative Study of the Safety and Contraceptive Efficacy of the Woman's Condom

The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder

Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates

A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.

GlowCaps Adherence Randomized Control Trial

Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver

Biomarkers in the Brain Oxygen Optimization in Severe Traumatic Brain Injury Trial